Advertisement

Metabolic Epoxidation of Aflatoxin B1 and its Metabolites: Patterns of DNA Adduct Formation and Removal in Relation to Biological Effects

  • John M. Essigmann
  • Robert G. Croy
  • Richard A. Bennett
  • Gerald N. Wogan
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 52)

Abstract

Aflatoxin B1 (AFB1) is the most toxic and carcinogenic member of a family of difuranocoumarins produced as secondary metabolites by strains of Aspergillus flavus and related fungi1. Exposure to aflatoxin is a public health hazard in technologically developing areas of the world, where AFB1-producing fungi are distributed widely and where food production and storage conditions are conducive to mold spoilage and consequent mycotoxin production. In most animals, the main target for the biological effects of AFB1 is the liver, although the relative sensitivity of different animal species varies markedly; the rat, rainbow trout and duck are highly sensitive whereas the mouse is resistant. The liver is also apparently a target in humans, in that a high incidence of hepatocellular carcinoma has been observed in chronically exposed populations2. Additional factors may act in concert in initiating the putative carcinogenic effects of AFB1 in humans; these include abnormal nutritional status or concomitant pathological conditions such as viral hepatitis.

Keywords

Imidazole Ring Major Adduct Urinary Compound Sensitive Analytical Methodology Adduct Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. N. Wogan, Aflatoxin carcinogenesis, in: “Methods in Cancer Research, Vol. III,” H. Busch, ed., Academic Press, New York, 1973, pp. 309–344.Google Scholar
  2. 2.
    G. N. Wogan, The induction of liver cell cancer by chemicals, in: “Liver Cell Cancer,” H. M. Cameron, D. A. Linsell, and G. P. Warwick, eds., Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands (1976).Google Scholar
  3. 3.
    D. H. Swenson, E. C. Miller, and J. A. Miller, Aflatoxin B1 2,3-oxide: Evidence for its formation in rat liver in vivo and by human liver microsomes in vitro, Biochem. Biophys. Res. Commun., 60: 1036 (1974).CrossRefGoogle Scholar
  4. 4.
    D. H. Swenson, J. K. Lin, E. C. Miller, and J. A. Miller, Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxin B1 and B2 to rat liver DNA and ribosomal RNA in vivo, Cancer Res., 37: 172 (1977).PubMedGoogle Scholar
  5. 5.
    J. M. Essigmann, R. G. Croy, A. M. Nadzan, W. F. Busby, Jr., V. N. Reinhold, G. Buchi, and G. N. Wogan, Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro, Proc. Natl. Acad. Sci. USA, 74: 1870 (1977).CrossRefGoogle Scholar
  6. 6.
    J. K. Lin, J. A. Miller, and E. C. Miller, 2,3-dihydro-2(guan-7-yl)-3-hydroxyaflatoxin B1, a major acid hydrolysis product of aflatoxin B1-DNA or -rRNA adducts formed in hepatic microsome mediated reactions and in rat liver in vivo, Cancer Res., 37: 4430 (1977).PubMedGoogle Scholar
  7. 7.
    R. G. Croy, J. M. Essigmann, V. N. Reinhold, and G. N. Wogan, Identification of the principal aflatoxin B1-DNA adduct formed in vivo in rat liver, Proc. Natl. Acad. Sci. USA, 75: 1745 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    H. Autrup, J. M. Essigmann, R. G. Croy, B. F. Trump, G. N. Wogan, and C. C. Harris, Metabolism of aflatoxin B1-DNA and identification of a major aflatoxin B1-DNA adduct formed in cultured human bronchus and colon, Cancer Res., 39: 694 (1979).PubMedGoogle Scholar
  9. 9.
    C. N. Martin and R. C. Garner, Aflatoxin B1-oxide generated by chemical or enzymatic oxidation of aflatoxin B1 causes guanine substitution in nucleic acids, Nature, 267: 863 (1977).PubMedCrossRefGoogle Scholar
  10. 10.
    G. H. Buchi, M. A. Francisco, J. M. Liesch, and P. F. Shuda, A new synthesis of aflatoxin M1, J. Am. Chem. Soc., 103: 3497 (1981).CrossRefGoogle Scholar
  11. 11.
    J. M. Essigmann, P. R. Donahue, D. L. Story, G. N. Wogan, and H. Brunengraber, Use of the isolated perfused rat liver to study carcinogen-DNA adduct formation from aflatoxin B1 and sterigmatocystin, Cancer Res., 40: 4085 (1980).PubMedGoogle Scholar
  12. 12.
    R. G. Croy and G. N. Wogan, Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys, J. Natl. Cancer Inst., 66: 761 (1981).PubMedGoogle Scholar
  13. 13.
    R. G. Croy and G. N. Wogan, Temporal patterns of covalent DNA adducts in rat liver after single and multiple doses of aflatoxin B1, Cancer Res., 41: 197 (1981).PubMedGoogle Scholar
  14. 14.
    R. A. Bennett, J. M. Essigmann, and G. N. Wogan, Excretion of an aflatoxin-guanine adduct in urine of aflatoxin B1-treated rats, Cancer Res., 41: 650 (1981).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • John M. Essigmann
    • 1
  • Robert G. Croy
    • 1
  • Richard A. Bennett
    • 1
  • Gerald N. Wogan
    • 1
  1. 1.Laboratory of Toxicology, Department of Nutrition and Food ScienceMassachusetts Institute of TechnologyCambridgeUSA

Personalised recommendations